Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund.

2024 saw good implementation of this strategy with the approval of subcutaneous Opdivo and FDA approval of the company's new drug Cobenfy, presenting prescribers with the first novel mechanism to ...

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

In this piece, we will look at the stocks Jim Cramer recently discussed.

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

For around 70 years, the treatment of schizophrenia has relied almost entirely on drugs that block dopamine receptors, so Cobenfy's action on cholinergic receptors offers a brand new way to treat ...

We recently published a list of 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Qorvo ...

Drugs for metabolic diseases ... 3) Bristol Myers Squibb's Cobenfy (KarXT; xanomeline and trospium chloride), a dual M1/M4 muscarinic acetylcholine receptor agonist for schizophrenia and psychosis ...

Cobenfy was approved by the U.S. Food and Drug Administration in September 2024 to treat adults with schizophrenia. Experts widely consider cognitive remediation therapy to be the best available ...

With Cobenfy now available for adults with schizophrenia, we look forward to further understanding the real-world impact of this differentiated treatment option,” Dr Johnson noted. The US Food and ...